Cargando…
Circulating adropin and vascular endothelial growth factor receptor-2 levels in age-related macular degeneration and T2DM patients—A cross-sectional study
BACKGROUND: Macular drusen formation and angiogenesis are the two chief processes associated with age-related macular degeneration. Adropin and vascular endothelial growth factor receptor-2 (VEGFR-2) may be involved in these pathologies. By altering lipid metabolism, adropin may contribute in the ea...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7652138/ https://www.ncbi.nlm.nih.gov/pubmed/33209815 http://dx.doi.org/10.4103/jfmpc.jfmpc_813_20 |
_version_ | 1783607645197828096 |
---|---|
author | Neethu, Areekulangara Jayashree, Kuppuswami Senthilkumar, Gandhipuram Periyasamy Ramesh Babu, K Vadivelan, Mehalingam |
author_facet | Neethu, Areekulangara Jayashree, Kuppuswami Senthilkumar, Gandhipuram Periyasamy Ramesh Babu, K Vadivelan, Mehalingam |
author_sort | Neethu, Areekulangara |
collection | PubMed |
description | BACKGROUND: Macular drusen formation and angiogenesis are the two chief processes associated with age-related macular degeneration. Adropin and vascular endothelial growth factor receptor-2 (VEGFR-2) may be involved in these pathologies. By altering lipid metabolism, adropin may contribute in the early stages of age-related macular degeneration (AMD). VEGFR-2 may participate in the later form of AMD, by promoting angiogenesis. This study compared the circulatory levels of adropin and VEGFR-2 in AMD and patients without AMD and assessed their association with disease severity, to understand their possible role in AMD. OBJECTIVES: This study aimed to assess and compare the serum levels of adropin and VEGFR-2 in patients with AMD and type 2 diabetes patients without AMD, and, to investigate the correlation between these two parameters with disease severity. METHODS: Our study involves two groups of 39 each. Group A (age-related macular degeneration) and Group B (diabetes patients without age-related macular degeneration). Routine parameters fasting blood sugar (FBS), lipid profile, and liver function tests (LFT) were estimated by using autoanalyzer. Serum adropin and VEGFR-2 were assessed by ELISA. RESULTS: Among the basic parameters, systolic blood pressure and fasting blood glucose alone were significantly different across the groups. We did not find significant alterations in adropin and VEGFR-2 levels between the study groups. Our lipid profile parameters (triglycerides and total cholesterol) have significant positive association. VEGFR-2 showed a positive correlation with the severity of AMD. Adropin did not exhibit any correlation with disease severity and with VEGFR-2. CONCLUSION: We could not find any observable alterations of statistical significance, in adropin and VEGFR-2 levels. VEGFR-2's correlation with disease severity could be important. Adropin might have subtler roles in AMD, though not evident from our study, and requires a deeper observation at the molecular level to elucidate its function. |
format | Online Article Text |
id | pubmed-7652138 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-76521382020-11-17 Circulating adropin and vascular endothelial growth factor receptor-2 levels in age-related macular degeneration and T2DM patients—A cross-sectional study Neethu, Areekulangara Jayashree, Kuppuswami Senthilkumar, Gandhipuram Periyasamy Ramesh Babu, K Vadivelan, Mehalingam J Family Med Prim Care Original Article BACKGROUND: Macular drusen formation and angiogenesis are the two chief processes associated with age-related macular degeneration. Adropin and vascular endothelial growth factor receptor-2 (VEGFR-2) may be involved in these pathologies. By altering lipid metabolism, adropin may contribute in the early stages of age-related macular degeneration (AMD). VEGFR-2 may participate in the later form of AMD, by promoting angiogenesis. This study compared the circulatory levels of adropin and VEGFR-2 in AMD and patients without AMD and assessed their association with disease severity, to understand their possible role in AMD. OBJECTIVES: This study aimed to assess and compare the serum levels of adropin and VEGFR-2 in patients with AMD and type 2 diabetes patients without AMD, and, to investigate the correlation between these two parameters with disease severity. METHODS: Our study involves two groups of 39 each. Group A (age-related macular degeneration) and Group B (diabetes patients without age-related macular degeneration). Routine parameters fasting blood sugar (FBS), lipid profile, and liver function tests (LFT) were estimated by using autoanalyzer. Serum adropin and VEGFR-2 were assessed by ELISA. RESULTS: Among the basic parameters, systolic blood pressure and fasting blood glucose alone were significantly different across the groups. We did not find significant alterations in adropin and VEGFR-2 levels between the study groups. Our lipid profile parameters (triglycerides and total cholesterol) have significant positive association. VEGFR-2 showed a positive correlation with the severity of AMD. Adropin did not exhibit any correlation with disease severity and with VEGFR-2. CONCLUSION: We could not find any observable alterations of statistical significance, in adropin and VEGFR-2 levels. VEGFR-2's correlation with disease severity could be important. Adropin might have subtler roles in AMD, though not evident from our study, and requires a deeper observation at the molecular level to elucidate its function. Wolters Kluwer - Medknow 2020-09-30 /pmc/articles/PMC7652138/ /pubmed/33209815 http://dx.doi.org/10.4103/jfmpc.jfmpc_813_20 Text en Copyright: © 2020 Journal of Family Medicine and Primary Care http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Neethu, Areekulangara Jayashree, Kuppuswami Senthilkumar, Gandhipuram Periyasamy Ramesh Babu, K Vadivelan, Mehalingam Circulating adropin and vascular endothelial growth factor receptor-2 levels in age-related macular degeneration and T2DM patients—A cross-sectional study |
title | Circulating adropin and vascular endothelial growth factor receptor-2 levels in age-related macular degeneration and T2DM patients—A cross-sectional study |
title_full | Circulating adropin and vascular endothelial growth factor receptor-2 levels in age-related macular degeneration and T2DM patients—A cross-sectional study |
title_fullStr | Circulating adropin and vascular endothelial growth factor receptor-2 levels in age-related macular degeneration and T2DM patients—A cross-sectional study |
title_full_unstemmed | Circulating adropin and vascular endothelial growth factor receptor-2 levels in age-related macular degeneration and T2DM patients—A cross-sectional study |
title_short | Circulating adropin and vascular endothelial growth factor receptor-2 levels in age-related macular degeneration and T2DM patients—A cross-sectional study |
title_sort | circulating adropin and vascular endothelial growth factor receptor-2 levels in age-related macular degeneration and t2dm patients—a cross-sectional study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7652138/ https://www.ncbi.nlm.nih.gov/pubmed/33209815 http://dx.doi.org/10.4103/jfmpc.jfmpc_813_20 |
work_keys_str_mv | AT neethuareekulangara circulatingadropinandvascularendothelialgrowthfactorreceptor2levelsinagerelatedmaculardegenerationandt2dmpatientsacrosssectionalstudy AT jayashreekuppuswami circulatingadropinandvascularendothelialgrowthfactorreceptor2levelsinagerelatedmaculardegenerationandt2dmpatientsacrosssectionalstudy AT senthilkumargandhipuramperiyasamy circulatingadropinandvascularendothelialgrowthfactorreceptor2levelsinagerelatedmaculardegenerationandt2dmpatientsacrosssectionalstudy AT rameshbabuk circulatingadropinandvascularendothelialgrowthfactorreceptor2levelsinagerelatedmaculardegenerationandt2dmpatientsacrosssectionalstudy AT vadivelanmehalingam circulatingadropinandvascularendothelialgrowthfactorreceptor2levelsinagerelatedmaculardegenerationandt2dmpatientsacrosssectionalstudy |